Compare Ascendis Pharma A/S (ASND) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs HSBC Holdings plc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while HSBC Holdings plc trades at $98.42 (market cap $333.00B). The key difference: HSBC Holdings plc is far larger — about 18.8× Ascendis Pharma A/S's market cap, and HSBC Holdings plc pays a 3.78% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HSBC | |
|---|---|---|
Market Cap | $17.74B | $333.00B |
Sector | Health | Technology |
52-Week High | $277.18 | $99.09 |
52-Week Low | $163.32 | $61.30 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HSBC trades at $99.09, up 1.09% today and near its 52-week high of $99.47. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Recent news highlights strategic moves, including a potential Turkey business sale and AI expansion with Google Cloud. Revenue is stable at $71.02B for 2025, with a net income margin of 30.81% and a P/E ratio of 16.38.
Outlook is cautiously optimistic, supported by earnings momentum and restructuring efforts. Risks include regulatory penalties and global economic sensitivity. Analysts are mixed, with 38.1% recommending buy. The dividend of $0.50 per share adds income appeal, but investors should monitor execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
